

		EMLc	ATC codes: J05AP07 J05AP08
Indication	Chronic hepatitis C	ICD11 code: 1E91.1	
INN	Daclatasvir + sofosbuvir		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg		
EML status history	First added in 2021 (TRS 1035) Changed in 2025 (TRS 1064)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	Medicines within the same pharmacological class can be used		
Therapeutic alternatives limitations	Pangenotypic direct-acting antiviral combinations		
Therapeutic alternatives limitations for EMLc	Pangenotypic direct-acting antiviral combinations		
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org  Read more about patents . 		
Wikipedia	Daclatasvir + sofosbuvir 		
DrugBank	Daclatasvir  , Sofosbuvir 		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.

